in vivo News and Research

RSS

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Study demonstrates accuracy of non-invasive test for NASH diagnosis

A Chinese study presented at the International Liver CongressTM 2013 has demonstrated the accuracy of a non-invasive test for non-alcoholic steatohepatitis (NASH) diagnosis.

26 Apr 2013

New device allows automatic suturing of large intestine during cancer colon surgery

The Spanish research centre Innotex has developed a device that enables automatic suturing of the large intestine after being sectioned during cancer colon surgery. The novelty of the system, called Insewing, is that it allows the use of absorbable suture material instead of metallic staples which are currently used and could cause intestinal stiffness and obstruction.

26 Apr 2013

New hope for patients with chronic HBV infection

Exciting new data presented today at the International Liver Congress- 2013 include rults from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.

25 Apr 2013

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

A consortium led by the Spanish National Cancer Research Centre's researcher Mar-a S. Soengas −Programme Director of the Centre-s Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance, the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

24 Apr 2013

Investigators report that cell-permeable NLS peptide shows promise in controlling atherosclerotic disease

Atherosclerosis - sometimes called "hardening of the arteries" - is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-ĸB nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease.

18 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.

6 Apr 2013

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.

5 Apr 2013

Non-invasive gut health testing breakthrough

Health and functional claims made for foods such as probiotics still need to prove their effectiveness ― an important part of the answer rests in our small intestines and their role in digestion, and immunity.

5 Apr 2013

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.

4 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

A team of UC Davis scientists has found that a product resulting from a metabolized omega-3 fatty acid helps combat cancer by cutting off the supply of oxygen and nutrients that fuel tumor growth and spread of the disease.

3 Apr 2013

V/Q imaging can detect early stages of COPD

In vivo ventilation/perfusion (V/Q) imaging can detect early changes to the lung caused by cigarette smoke exposure and provides a noninvasive method for studying lung dysfunction in preclinical models, according to research published in the April issue of The Journal of Nuclear Medicine.

2 Apr 2013

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

There are two regions in the brain that continue to produce new neurons well into adulthood. One of these regions is the hippocampus and as we converse this region is actively involved in memory formation, mood regulation and cognition.

2 Apr 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

in vivo News and Research

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Study demonstrates accuracy of non-invasive test for NASH diagnosis

New device allows automatic suturing of large intestine during cancer colon surgery

New hope for patients with chronic HBV infection

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

Investigators report that cell-permeable NLS peptide shows promise in controlling atherosclerotic disease

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

Non-invasive gut health testing breakthrough

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

Polymer scaffolds can advance the development of cancer therapeutics

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

V/Q imaging can detect early stages of COPD

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News